# FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL						
OMB Number:	3235-0287					
Estimated average burden						
hours per response	0.5					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person *  MCLAUGHLIN JOHN				2. Issuer Name <b>and</b> Ticker or Trading Symbol Sonoma Pharmaceuticals, Inc. [SNOA]							A]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  _X_ Director 10% Owner Officer (give title below) Other (specify below)						
(Last) (First) (Middle) C/O SONOMA PHARMACEUTICALS, INC., 1129 N. MCDOWELL BLVD.				3. Date of Earliest Transaction (Month/Day/Year) 11/29/2017							ny/Year)							
(Street) PETALUMA, CA 94954				4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting PersonForm filed by More than One Reporting Person						
(City)	·)	(State)		(Zip)	Table I - Non-Derivative Securities Acqui					ired, Disposed of, or Beneficially Owned								
1.Title of Security (Instr. 3)		Date		th/Day/Year)	Exect any		eemed ion Date, if n/Day/Year)		f Code (Instr. 8)		(A) or (D)	4. Securities Acqui (A) or Disposed of (D) (Instr. 3, 4 and 5)		Beneficia	ally Owned Following I Transaction(s)		Ownership Form: H Direct (D)	Beneficial Ownership
									ode	V	Amou	(A) or	Price				or Indirect (I) (Instr. 4)	Instr. 4)
Common value per	Stock, \$0. share	0001 par	11/29	9/2017				1	A		14,31	7 A	<u>(1)</u>	27,778			D	
indirectly.				Table II - D					t quire	conta the fo	ained i orm di sposed	n this for splays a	rm ar curre eficia	e not required to the second s	uired to re	nformation espond unl ntrol numb	ess	C 1474 (9- 02)
Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		Year)	3A. Deemed Execution Da any	4. Transactic Code Year) (Instr. 8)		tion			6. Date Exercisable and Expiration Date		7. T Am Und Sec	Title and ount of derlying urities str. 3 and	Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction ((Instr. 4)	Ownership Form of Derivative Security: Direct (D) or Indirect	))	
						Code	V	(A)	(D)	Date Exer	cisable	Expiration Date	n Titl	Amount or e Number of Shares				
Repor	ting O	wners																

Describer Owner Verse / Address	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
MCLAUGHLIN JOHN C/O SONOMA PHARMACEUTICALS, INC. 1129 N. MCDOWELL BLVD. PETALUMA, CA 94954	X						

## **Signatures**

/s/ Robert Miller as attorney-in-fact	12/01/2017
**Signature of Reporting Person	Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The stock was granted by the Issuer as a quarterly retainer as well as an annual grant pursuant to the Non-Employee Director Compensation Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

